Interfering Virus: A New Treatment Strategy For Flu
Executive Summary
The UK's VirionHealth has taken £13m on board in a Series A to develop a novel approach to the treatment of influenza virus infections.
You may also be interested in...
Israel's BiondVax To Take 'More Global View' With NASDAQ-Only Listing
BiondVax's CEO tells Scrip why the Israel-based vaccine maker wants to delist there and only have a US-based NASDAQ listing and re-make its executive board in to one that's more internationally experienced.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.